Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is very common in type 2 diabetes individuals and can progress to fibrosis and hepatocellular carcinoma if not detected and treated early. The term MASLD includes a spectrum of steatotic liver diseases along with the presence of two or more components of the metabolic syndrome in individuals where the liver pathology cannot be explained by alcohol intake. In this review article, we look at the various conventional treatment modalities like diabetic agents and non-diabetic agents as well as new treatment modalities like resmetirom, glucagon like peptide-1 (GLP-1) agonists, and dual GLP-1/GIP agonists for hepatic steatosis and fibrosis and summarize their mechanism of action and their effect on hepatic steatosis, progression, and regression of fibrosis in Table 1 and Table 2 respectively.